Literature DB >> 29499226

Clinicopathologic significance of HLA-G and HLA-E molecules in Tunisian patients with ovarian carcinoma.

Wafa Babay1, Hamza Ben Yahia1, Nadia Boujelbene2, Nour Zidi3, Ahmed Baligh Laaribi1, Dhikra Kacem4, Radhia Ben Ghorbel4, Abdellatif Boudabous1, Hadda-Imene Ouzari1, Roberta Rizzo5, Vera Rebmann6, Karima Mrad2, Inès Zidi7.   

Abstract

BACKGROUND: The human leukocyte antigen (HLA)-G and HLA-E, non classical HLA class I molecules, have been highly implicated in immune tolerance. HLA-G and HLA-E molecules were proposed as putative markers of several advanced cancers. As a step towards a better understanding of ovarian carcinoma, we evaluated the expression of both HLA-G and HLA-E molecules and explored their prognostic implication.
METHODS: HLA-G and HLA-E expression were studied by immunohistochemistry on ovarian carcinoma tissues. This expression was semi-quantitatively scored into four expression groups and correlated to clinicopathological parameters and patients' survival.
RESULTS: HLA-G and HLA-E have been found to be highly expressed in ovarian carcinoma tissues (Respectively, 72.4% and 96.8%). They are frequently co-expressed. Univariate and multivariate analysis revealed that a positive HLA-G expression status in tumor tissue is a promising candidate parameter to predict disease recurrence in addition to the disease status in Tunisian patients with ovarian carcinoma. Moreover, the elevated HLA-E expression was associated with serous ovarian carcinoma subtype as well as with advanced stages of ovarian carcinoma.
CONCLUSION: HLA-G and HLA-E are highly represented in ovarian carcinoma suggesting a potential association with progressive disease mechanism. HLA-G and HLA-E molecules might be new candidates' markers for ovarian carcinoma progression.
Copyright © 2018 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HLA-E; HLA-G; Ovarian carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29499226     DOI: 10.1016/j.humimm.2018.02.012

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  The relationship of 3'UTR HLA-G14-bp insertion/deletion and +3142 C/G polymorphisms and soluble HLA-G expression with gynecological cancers: An updated meta-analysis.

Authors:  Kalthoum Tizaoui; Maroua Jalouli; Nadia Boujelbene; Abdel Halim Harrath; Hadda-Imene Ouzari; Roberta Rizzo; Inès Zidi
Journal:  Immun Inflamm Dis       Date:  2022-07

2.  HLA-G 3' untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer.

Authors:  Esther Schwich; Vera Rebmann; Rafael Tomoya Michita; Hana Rohn; Jan Willem Voncken; Peter A Horn; Rainer Kimmig; Sabine Kasimir-Bauer; Paul Buderath
Journal:  Sci Rep       Date:  2019-04-01       Impact factor: 4.379

Review 3.  HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers.

Authors:  Peilong Li; Nan Wang; Yi Zhang; Chuanxin Wang; Lutao Du
Journal:  Front Immunol       Date:  2021-11-11       Impact factor: 7.561

4.  Construction of a Macrophage Infiltration Regulatory Network and Related Prognostic Model of High-Grade Serous Ovarian Cancer.

Authors:  Hua Chang; Yuyan Zhu; Jiahui Zheng; Lian Chen; Jiaxing Lin; Jihang Yao
Journal:  J Oncol       Date:  2021-11-24       Impact factor: 4.375

5.  Predicting the most deleterious missense nsSNPs of the protein isoforms of the human HLA-G gene and in silico evaluation of their structural and functional consequences.

Authors:  Elaheh Emadi; Fatemeh Akhoundi; Seyed Mehdi Kalantar; Modjtaba Emadi-Baygi
Journal:  BMC Genet       Date:  2020-08-31       Impact factor: 2.797

Review 6.  HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.